Literature DB >> 29430235

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment.

Lieke van Montfort1, Caroline M Loos2, Monique Anten2, Rob L H Jansen1.   

Abstract

Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab, nivolumab, and pembrolizumab. Nowadays, ipilimumab is often used in patients with metastatic melanoma. In this paper, we report a case of a 68-year-old man who developed, and eventually died of, herpes encephalitis after introducing ipilimumab as treatment for metastatic melanoma. To our knowledge, this is the first report in which herpes encephalitis as a complication after ipilimumab and infliximab treatment is described and we would like to make physicians aware of this possible serious neurological complication, especially when a patient has a history of herpes simplex infection.

Entities:  

Keywords:  CTLA-4 antigen; Herpes simplex encephalitis; Immunotherapy; Ipilimumab; Melanoma; Neuro-oncology tumor necrosis factor; Side effects

Year:  2017        PMID: 29430235      PMCID: PMC5803703          DOI: 10.1159/000484553

Source DB:  PubMed          Journal:  Case Rep Oncol        ISSN: 1662-6575


  8 in total

1.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.

Authors:  Pascale Dequen; Paul Lorigan; Jeroen P Jansen; Marc van Baardewijk; Mario J N M Ouwens; Srividya Kotapati
Journal:  Oncologist       Date:  2012-09-28

3.  Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-α monoclonal antibodies.

Authors:  Kinda Schepers; Antonio Hernandez; Graciela Andrei; Sarah Gillemot; Pierre Fiten; Ghislain Opdenakker; Jean-Christophe Bier; Philippe David; Marie-Luce Delforge; Frédérique Jacobs; Robert Snoeck
Journal:  J Clin Virol       Date:  2013-10-31       Impact factor: 3.168

4.  Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2.

Authors:  Patric Lundberg; Paula V Welander; Carl K Edwards; Nico van Rooijen; Edouard Cantin
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 5.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 6.  Cross-regulation between herpesviruses and the TNF superfamily members.

Authors:  John R Sedý; Patricia G Spear; Carl F Ware
Journal:  Nat Rev Immunol       Date:  2008-11       Impact factor: 53.106

7.  Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.

Authors:  Russell D Bradford; April C Pettit; Patty W Wright; Mark J Mulligan; Larry W Moreland; David A McLain; John W Gnann; Karen C Bloch
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

Review 8.  Herpes simplex virus encephalitis during treatment with etanercept.

Authors:  Robbert H J Crusio; Stephanie V Singson; Faysal Haroun; Hetal H Mehta; David M Parenti
Journal:  Scand J Infect Dis       Date:  2013-11-15
  8 in total
  1 in total

1.  Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.

Authors:  Cristina Scavone; Maurizio Sessa; Emilio Clementi; Giovanni Corrao; Roberto Leone; Alessandro Mugelli; Francesco Rossi; Edoardo Spina; Annalisa Capuano
Journal:  BioDrugs       Date:  2018-12       Impact factor: 5.807

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.